-
1
المؤلفون: Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
المساهمون: CCA - Cancer Treatment and quality of life, Medical oncology
المصدر: Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110Test
Journal of Clinical Oncology, 38, 33, pp. 3925-3936مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Medizin, Pembrolizumab, Placebo, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Stage III melanoma, Melanoma, Chemotherapy, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Adjuvant
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c8d8800862ec580f808001677c9a85Test
https://hdl.handle.net/2066/228545Test -
2
المؤلفون: Christian U. Blank, Stéphane Dalle, Alexander M.M. Eggermont, Sandrine Marreaud, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Stefan Suciu, Nageatte Ibrahim, Rahima Jamal, Paolo A. Ascierto, Alexander C.J. van Akkooi, Michal Kicinski, Piotr Rutkowski, Georgina V. Long, Dirk Schadendorf, Ralf Gutzmer, Shahneen Sandhu, Andrew Haydon, Victoria Atkinson, Susana Puig, Adnan Khattak, Anna Maria Di Giacomo, Clemens Krepler, Mario Mandalà, Rutger H. T. Koornstra, Caroline Robert, Jean-Jacques Grob, Leonel Hernandez-Aya, Paul Lorigan, James Larkin
المساهمون: Medical oncology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Jama Oncology, 6, 519-527
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial ', JAMA Oncology, vol. 6, no. 4, pp. 519-527 . https://doi.org/10.1001/jamaoncol.2019.5570Test
Eggermont, A M M, Kicinski, M, Blank, C U, Mandala, M, Long, G V, Atkinson, V, Dalle, S, Haydon, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Krepler, C, Ibrahim, N, Marreaud, S, van Akkooi, A, Robert, C & Suciu, S 2020, ' Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo : A Secondary Analysis of a Randomized Clinical Trial ', JAMA oncology . https://doi.org/10.1001/jamaoncol.2019.5570Test
Jama Oncology, 6, 4, pp. 519-527
JAMA Oncology, 6(4), 519-527. American Medical Associationمصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Population, Medizin, Pembrolizumab, Placebo, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Placebos, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Melanoma, Aged, Neoplasm Staging, Proportional Hazards Models, education.field_of_study, Manchester Cancer Research Centre, business.industry, Proportional hazards model, ResearchInstitutes_Networks_Beacons/mcrc, Hazard ratio, Middle Aged, Ipilimumab, Clinical trial, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9b431bc34ae329792ac7bd923376806Test
https://hdl.handle.net/2066/218502Test -
3
المؤلفون: Paolo A. Ascierto, Dirk Schadendorf, Selma Ugurel, Alexander M.M. Eggermont, Reinhardt Dummer, Elisabeth Livingstone, Lisa Zimmer, Anne Zaremba, Georgina V. Long, Caroline Robert
المساهمون: University of Zurich, Schadendorf, Dirk
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Medizin, 610 Medicine & health, Pembrolizumab, Targeted therapy, chemistry.chemical_compound, Internal medicine, medicine, Humans, 1306 Cancer Research, Immune Checkpoint Inhibitors, Melanoma, Entinostat, business.industry, 10177 Dermatology Clinic, Immune checkpoint, Clinical trial, chemistry, 2730 Oncology, Immunotherapy, Nivolumab, business, Lenvatinib, Adjuvant
وصف الملف: 906_Zaremba_A._et_al._The_concepts_of_rechallange_and_retreatment_with_immune_checkpoints_blockade_in_melanoma_patients_EJC_2021.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af59f477caa0569ca2410181854e889Test
https://www.zora.uzh.ch/id/eprint/206131Test/ -
4
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
5
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
6
المؤلفون: Christian U. Blank, Mario Mandalà, Caroline Robert, Rutger H. T. Koornstra, Shahneen Sandhu, Susana Puig, Piotr Rutkowski, Ralf Gutzmer, Andrew M. Haydon, Andrey Meshcheryakov, Anna Maria Di Giacomo, Clemens Krepler, Victoria Atkinson, Leonel Hernandez-Aya, Adnan Khattak, James Larkin, Matteo S. Carlino, Alfonsus J. M. van den Eertwegh, Jean-Jacques Grob, Alexander M.M. Eggermont, Georgina V. Long, Michal Kicinski, Dirk Schadendorf, Alexander C.J. van Akkooi, Nageatte Ibrahim, S. Dalle, Paolo A. Ascierto, Stefan Suciu, Rahima Jamal, Sandrine Marreaud, Paul Lorigan
المصدر: Journal of Clinical Oncology, 39, 8, pp. 944-946
Journal of Clinical Oncology, 39, 944-946مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, MEDLINE, Medizin, Pembrolizumab, Adjuvant therapy, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], Text mining, Clinical trials, Internal medicine, Recurrence free survival, Medicine, Staging systems, Risk of relapse, Metastatic relapse, business.industry, Melanoma, Stage at diagnosis, medicine.disease, Clinical trial, Hormonal therapy, pembrolizumab, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c843a2657530330474a766f083b07e20Test
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102657696Test -
7
المؤلفون: Anna Maria Di Giacomo, Georgina V. Long, Vanna Chiarion-Sileni, Helen Gogas, Micaela Hernberg, Kerry J. Savage, Laurent Mortier, Francesco Cognetti, Benjamin Brady, Cornelia Mauch, Caroline Robert, Julie Charles, Ana Arance, Piotr Rutkowski, Catriona M. McNeil, Lars Ny, Jesus Zoco, Ewa Kalinka, Sandra Re, Dirk Schadendorf, Victoria Atkinson, Caroline Dutriaux, Catalin Mihalcioiu, Paolo A. Ascierto, Jessica C. Hassel, Henrik Schmidt, Céleste Lebbé
المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology, Helsinki University Hospital Area
المصدر: Journal of Clinical Oncology
Robert, C, Long, G V, Brady, B, Dutriaux, C, Di Giacomo, A M, Mortier, L, Rutkowski, P, Hassel, J C, McNeil, C M, Kalinka, E A, Lebbé, C, Charles, J, Hernberg, M M, Savage, K J, Chiarion-Sileni, V, Mihalcioiu, C, Mauch, C, Arance, A, Cognetti, F, Ny, L, Schmidt, H, Schadendorf, D, Gogas, H, Zoco, J, Re, S, Ascierto, P A & Atkinson, V 2020, ' Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3937-3946 . https://doi.org/10.1200/JCO.20.00995Testمصطلحات موضوعية: 0301 basic medicine, Oncology, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, 3122 Cancers, Medizin, Ipilimumab, Pembrolizumab, law.invention, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Internal medicine, Original Reports, medicine, Humans, METASTATIC MELANOMA, Progression-free survival, PEMBROLIZUMAB, Survival rate, Melanoma, Antineoplastic Agents, Alkylating, COMPLETE RESPONSE, business.industry, IPILIMUMAB, Wild type, Progression-Free Survival, 3. Good health, Clinical trial, Dacarbazine, Survival Rate, 030104 developmental biology, Nivolumab, 030220 oncology & carcinogenesis, SURVIVAL, Metastatic melanoma, Complete response, Pembrolizumab, Ipilimumab, Survival, business, medicine.drug
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e136a7f3cebfa513b285e44ed047f9Test
http://hdl.handle.net/10138/324446Test -
8
المؤلفون: Ana Arance, Marta Nyakas, Nageatte Ibrahim, Igor Puzanov, Antoni Ribas, Reinhard Dummer, Jianxin Lin, Robin Mogg, Caroline Robert, Dirk Schadendorf, Ahmad A. Tarhini, Kim Margolin, Blanca Homet Moreno, Omid Hamid, Jacob Schachter, Matteo S. Carlino, Jose Lutzky, Paolo A. Ascierto, Steven J. O'Day, Adil Daud, Georgina V. Long
المصدر: JAMA Oncol
مصطلحات موضوعية: Oncology, Male, Proto-Oncogene Proteins B-raf, Cancer Research, medicine.medical_specialty, Medizin, Subgroup analysis, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, Double-Blind Method, Internal medicine, Medicine, Humans, 030212 general & internal medicine, neoplasms, Melanoma, Protein Kinase Inhibitors, Survival analysis, Original Investigation, Aged, Mitogen-Activated Protein Kinase Kinases, business.industry, MEK inhibitor, Middle Aged, medicine.disease, Survival Analysis, Clinical trial, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Mutation, Population study, Female, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a942c45d9a0d560a1e0582292a5fe85Test
https://europepmc.org/articles/PMC7366279Test/ -
9
المؤلفون: Christian U. Blank, Scot Ebbinghaus, Reinhard Dummer, Carmen Loquai, Steven J. O'Day, Antoni Ribas, Adil Daud, Jacob Schachter, Caroline Robert, Janice M. Mehnert, Dirk Schadendorf, S. Peter Kang, Wei Zhou, Igor Puzanov, Darcy A. Hille, April K.S. Salama, Omid Hamid, Lee D. Cranmer, Alfons J.M. van den Eertwegh, Axel Hauschild
المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development
المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamonمصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma
وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
https://doi.org/10.1016/j.ejca.2016.07.018Test -
10
المؤلفون: Honghong Zhou, Caroline Robert, Georgina V. Long, Gil Bar-Sela, Christoph Hoeller, Christian U. Blank, Matteo S. Carlino, Dirk Schadendorf, Catherine Barrow, Antoni Ribas, Christian Caglevic, Adil Daud, Erika Richtig, Ahmed Tarhini, Erin Jensen, Pascal Wolter, Nageatte Ibrahim, Kenneth Emancipator, Marta Nyakas, Scot Ebbinghaus
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Adolescent, Medizin, Ipilimumab, Kaplan-Meier Estimate, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Drug Administration Schedule, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, Humans, Medicine, In patient, Clinical significance, Melanoma, Aged, Advanced melanoma, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, Clinical trial, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379a23f5eaed8008bb5457e825ae223bTest
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85051002457Test